Zhangjiang Pharma Valley Firms Achieve Milestones: Mabwell Pursues HK IPO, Insilico Announces BD Deal, OYMotion and Fengtai Raise New Funding

Recently,Zhangjiang Pharm Valley Company MabwellSubmitted a prospectus to the Hong Kong Stock Exchange, planning to list on the Main Board of Hong Kong.

Mabwell, established in 2017 and located in Zhangjiang, Shanghai, is a renowned Chinese pharmaceutical company known for its innovative capabilities in drug research and development as well as its end-to-end capabilities from drug discovery to commercial sales. The company primarily focuses on the independent development of oncology and age-related disease drugs, covering fields such as oncology, immunology, ophthalmology, and orthopedics.

(Image Source: Zhangjiang Headlines)

The core product of the company, 9MW2821 (bulumtatug fuvedotin (BFv), an ADC candidate targeting Nectin-4), is currently the fastest-progressing Nectin-4-targeted ADC in clinical development in China for the treatment of urothelial carcinoma, second only to Padcev.

9MW2821 is also the world's first Nectin-4-targeted ADC to enter the pivotal Phase III trial stage for cervical cancer. Mabwell is currently conducting multiple clinical trials of 9MW2821, including a Phase III trial of 9MW2821 for the treatment of urothelial carcinoma, a Phase III trial of 9MW2821 for the treatment of cervical cancer, a Phase II trial of 9MW2821 for the treatment of triple-negative breast cancer, and a Phase II clinical trial of 9MW2821 for the treatment of advanced esophageal cancer. In addition, four of Mabwell's products—Junmaikang®, Maiweijian® (oncology), Mailishu® (orthopedics), and Mailisheng® (febrile neutropenia)—have been successfully launched.

Recently,OYMotion in Zhangjiang Pharm ValleyOYMotion Announces Completion of Series C1 Financing: Led by Shenzhen Brain Science and Brain-Inspired Intelligence Industry Investment Fund under CICC Capital, with Continuous Follow-up Investments from Multiple Existing Shareholders. OYMotion is the First Investment of CICC Brain Science Fund.

It is reported that OYMotion Technology Co., Ltd. successively received investments from the actual controller of Sanbo Brain Group and Tianjin Harvest Capital in 2023 and 2025. Currently, it is the only brain-computer interface enterprise in China that has been invested in by two professional brain science-themed investment funds. The company's shareholder lineup has been further upgraded, forming a dual strategic empowerment structure of "professional brain science fund + publicly listed healthcare industry party."

OYMotion ROHand Dexterous Hand Family

(Image Source: OYMotion)

OYMotion is the first technology enterprise in China to achieve large-scale commercial application of brain-computer interface technology. The company focuses on non-invasive neural signal sensing and AI analysis technology, independently developing core products such as EMG/EEG sensors, intelligent bionic hands, neurorehabilitation exoskeletons, and embodied intelligent dexterous hands. It owns more than a hundred independent intellectual property rights, with both technological maturity and cost control at the leading position in the industry.

Recently,Zhangjiang Pharm Valley Enterprise Fengtide PharmaAnnounced the completion of an $89 million Series B financing round, which was oversubscribed.

This B-round financing was jointly led by LAV, a globally renowned biopharmaceutical venture capital firm, and Foresite Capital, with participation from several well-known investment institutions such as QuanChuang Capital, HANCON Capital, RA Capital Management, and Logos Capital.

In addition, Fengtide Pharmaceuticals' existing investors, Orbimed and Qiming Venture Partners, also continued to increase their investment, jointly completing this round of oversubscribed financing. As of the completion of this round of financing, Fengtide Pharmaceuticals has cumulatively raised US$134 million, which will lay a solid foundation for the advancement of its subsequent pipeline.